white → brown2
DPT
N,N-Dipropyltryptamine
The Light
DPT is a synthetic psychedelic of the tryptamine class1, closely related to DMT. First described in the scientific literature by the late 1950s, it was subsequently investigated during the 1970s as an adjunct in therapeutic settings for alcoholism2 and to facilitate peak experiences in terminal cancer patients. DPT is noted for producing hallucinogenic effects comparable in intensity to DMT, though with greater unpredictability and wider individual variation in response at any given dose.
Dosage & Duration
Dosage
Threshold~50 mg
Light50-125 mg
Moderate125-250 mg
Strong250-350 mg
Heavy350+ mg
Oral bioavailability is relatively low, and individual responses can vary considerably. The onset of effects is influenced by whether the stomach is empty or contains food. Community reference timings for this route are contextual rather than clinical: PsychonautWiki lists oral total 2–4 hours, onset 20–60 minutes, and after-effects 2–3 hours, and does not establish come-up, peak, or offset values.3
Duration
Onset20-60 minutes
After Effects2-3 hours
Total2-4 hours
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
At light to moderate doses, there is often a slight sense of anaesthetization and relaxation. As the dose increases, perceptions of heart rate increase and body tremors and loss of muscle control are often reported. DPT can range from strong euphoria and erotiscism to nausea and dysphoria even within the same trip.
Cognitive
Visual
Distortions
Hallucinatory States
DPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of any other commonly used psychedelic.
Pharmacology
Pharmacodynamics
DPT acts primarily as a serotonin 5-HT2A receptor agonist.18 In rodent studies, selective 5-HT2A receptor antagonists effectively block the behavioral actions of the compound, and in discriminative stimulus assays DPT fully substitutes for DOM with this substitution likewise blocked by 5-HT2A antagonism. The modulatory effects of a 5-HT1A receptor antagonist suggest an additional 5-HT1A-mediated component, with partial agonism at this receptor proposed. DPT is an agonist at several serotonin receptors in vitro, though its full receptor interaction profile remains incompletely characterized. Research in mouse models of fragile X syndrome has found that certain pharmacological actions of DPT appear to be independent of serotonin 5-HT2A, 5-HT1A, 5-HT1B, and sigma-1 receptor activation, suggesting the compound may also act through non-serotonergic pathways.
Pharmacokinetics
Controlled pharmacokinetic studies have not characterized DPT in humans or other species. A 2024 fatal intoxication report measured DPT at approximately 210 ng/mL in serum collected four hours after reported intranasal use, 110 ng/mL in postmortem cardiac blood, and 180 ng/mL in urine. Because the consumed dose was unknown and the report did not provide serial concentration-time sampling, it does not establish route bioavailability, clearance, elimination half-life, or metabolic pathways; those parameters remain unknown.910
Metabolitesnone documented yet
Tolerance
Full Tolerance
Unlike most psychedelics, DPT does not appear to produce significant tolerance with repeated use. Animal studies have demonstrated that tolerance to DPT's effects does not develop, and human reports suggest only minimal tolerance building compared to other tryptamines.
Cross Tolerance
DMT (reported slight cross-tolerance, though less pronounced than with other psychedelics)
Harm Potential
Addiction & Dependence
Psychological
Extremely LowDPT is not habit-forming and the desire to use it can actually decrease with use. As with most psychedelics, it is reported to be self-limiting.11
Physical
Extremely LowNo physical dependence or withdrawal symptoms have been documented. The substance is reported to be self-limiting like other psychedelic tryptamines.11
Psychosis Risk
There is some potential for temporary psychosis during the experience. Transient anxiety and paranoia are more commonly reported adverse psychological effects. The substance is considered more psychologically challenging than many other psychedelics, with experiences often described as 'bizarre' and 'unsettling.' Those with existing psychiatric disorders should avoid this substance.12
Seizure Risk
One death has been associated with DPT and seizures, though the dose is unknown. Animal research indicates complex dose-dependent effects: at lower doses DPT demonstrated anticonvulsant properties in mouse models, while at higher doses it switched to proconvulsant action.9 Psychedelics may act as triggers for seizures in predisposed individuals.
History & Culture
Synthesis and Early Research
DPT was first synthesized in 1950, with initial pharmacological testing conducted in dogs by 1954. The compound was formally described in scientific literature by 1959, and human trials during the 1960s confirmed its hallucinogenic properties. By 1968, DPT had been identified as a novel designer
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
DPT is not individually listed in the current schedules to the 1961 Single Convention, the 1971 Convention on Psychotropic Substances, or the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
By Country
United StatesNot scheduled
DPT remains unscheduled at the federal level, meaning possession, purchase, and distribution are generally legal under federal law. However, several states have independently scheduled the substance: Florida classifies it as Schedule I, Maine lists it as Schedule X, and Oklahoma has placed it in Schedule I. The Federal Analogue Act may apply if sold for human consumption.
BelgiumIllegal (analog/blanket ban)Annexe IVa
Listed in Belgium's most restrictive controlled substance category, approximately equivalent to Schedule II under the United States system. Manufacturing, distribution, and possession are prohibited.
FinlandRestrictedLiite
Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista (1130/2014)2021
DPT (N,N-dipropyltryptamine) is listed in the annex to Finland's Government Decree on psychoactive substances prohibited from the consumer market. Section 1 of the decree makes the substances named in that annex prohibited psychoactive substances for the consumer market.
GreeceControlled substance
Became a controlled substance on February 18, 2003 under national drug legislation.
JapanIllegal指定薬物
Controlled under the Pharmaceutical Affairs Law. Possession and sale are prohibited.
New ZealandIllegalClass A
The Misuse of Drugs Act 1975 lists dipropyltryptamine (DPT) in Schedule 1 as a Class A controlled drug. The Act treats Schedule 1 substances as Class A controlled drugs and regulates their possession, supply, manufacture, importation, and exportation.
PolandIllegalZałącznik nr 3
Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2024 poz. 1139)363738
DPT (N,N-dipropylotryptamine) is listed as a new psychoactive substance in Annex 3 to the Minister of Health's regulation. It has been listed since 6 April 2021, when the amending regulation entered into force. Possession contrary to the Act on Counteracting Drug Addiction is punishable by a fine; possession of a considerable quantity may also result in restriction of liberty or imprisonment for up to three years.
SingaporeIllegalClass A Drugs
Singapore's Misuse of Drugs Act 1973 lists N,N-Dipropyltryptamine (DPT) as a Class A drug in the First Schedule. The Act defines a substance specified in the First Schedule as a controlled drug and regulates its possession, consumption, trafficking, import, export and manufacture.
SwitzerlandVerzeichnis E
Specifically named as a controlled substance under Verzeichnis E (Schedule E) of Swiss narcotics legislation. Unauthorized possession, production, and distribution are prohibited.
United KingdomIllegal (analog/blanket ban)Class A
Misuse of Drugs Act 1971, Schedule 245
Controlled under the Misuse of Drugs Act 1971 through the tryptamine catch-all clause, which covers compounds structurally derived from tryptamine by substitution at the nitrogen atom of the sidechain with alkyl substituents.46 Class A classification carries the most severe penalties for possession, production, and distribution.
AustraliaIllegal (analog/blanket ban)Schedule 9
DPT (N,N-dipropyltryptamine) is covered in Australia as a tryptamine derivative in Schedule 9 of the Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. Schedule 9 is the Poisons Standard classification for prohibited substances, and the derivative entry applies unless a substance is included in Schedule 4. The Standard is made under the Therapeutic Goods Act 1989 and is used by states and territories in their poisons-control laws governing possession, manufacture and supply.
DenmarkIllegalListe B
DPT (dipropyltryptamin) is listed in Liste B of Denmark's Bekendtgørelse om euforiserende stoffer, which entered into force on 29 March 2026. Substances in Liste B may be used only for medical and scientific purposes. Their import, export, sale, purchase, delivery, receipt, manufacture, processing, and possession are permitted only in accordance with the Order's controls.
GermanyIllegal (analog/blanket ban)Anlage 1
IrelandIllegal (analog/blanket ban)Schedule 1
DPT is a Schedule 1 controlled drug because it is structurally derived from tryptamine by di-n-propyl substitution at the side-chain nitrogen, a class expressly included in the Schedule. Unauthorised possession is an offence, and the Regulations prohibit production, supply, importation and exportation except as authorised.
LatviaIllegal (analog/blanket ban)I saraksts
Classified as a Schedule I controlled substance under national drug legislation. Possession, distribution, and production are illegal.
NorwayIllegalNarkotikalisten
Forskrift om narkotika (narkotikaforskriften) (FOR-2013-02-14-199), read with lov om legemidler m.v. (legemiddelloven) § 243435
DPT (N,N-dipropyltryptamine) is listed in Norway’s Narkotikalisten, which forms part of the Narcotics Regulation; the regulation has been in force since 14 February 2013. Possession or use of narcotics without lawful authority is prohibited, while manufacture, import, wholesale activity, retail sale, supply and dispatch are subject to the controls and permissions in the Medicines Act.
PortugalTable II-A
Listed in Table II-A of the controlled substances tables alongside substances such as MDMA and LSD. Production and trafficking remain illegal; personal possession of small quantities is decriminalized under Portuguese drug policy.
SwedenIllegalNarkotika
Classified as a narcotic substance on January 26, 2016 following its sale as a designer drug.43 Manufacturing, trade, and possession are prohibited.
UkraineIllegal (analog/blanket ban)Список № 2
Cabinet of Ministers Resolution No. 770 of 6 May 2000, On Approval of the List of Narcotic Drugs, Psychotropic Substances and Precursors44
DPT is covered as a derivative of the tryptamine group in List No. 2 of Table I of Ukraine’s controlled-substances schedule. List No. 2 classifies especially dangerous psychotropic substances whose circulation is prohibited; its derivative clause excludes medicinal products, including active pharmaceutical ingredients, containing tryptamine derivatives. The schedule was approved by Cabinet of Ministers Resolution No. 770 of 6 May 2000.
References
Source Pages
Citations
- Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, & Winter JC. (2008). Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents. Pharmacology Biochemistry and Behavior, 88(3), 358-365. https://doi.org/10.1016/j.pbb.2007.09.00712
- Grof S, Soskin RA, Richards WA, & Kurland AA. (1973). DPT as an adjunct in psychotherapy of alcoholics. International Pharmacopsychiatry, 8(1), 104-115. https://doi.org/10.1159/00046797912
- Community substance factsheet; retrieved 2026-08-16. psychonautwiki.org (n.d.). https://psychonautwiki.org/wiki/DPT1234
- Created 1998; modified 2015; accessed 2026-08-16. erowid.org (n.d.). https://www.erowid.org/chemicals/dpt/dpt_dose.shtml123
- DPT structured drug record. tripbot.tripsit.me (n.d.). https://tripbot.tripsit.me/api/tripsit/getDrug/DPT123
- Dipropyltryptamine (DPT). thedrugclassroom.com (n.d.). https://thedrugclassroom.com/video/dipropyltryptamine-dpt/123
- Low doses of dipropyltryptamine in psychotherapy. doi.org (n.d.). https://doi.org/10.1001/archpsyc.1973.017503600470061
- Jun-Xu Li, Kenner C Rice, & Charles P France. (2007). Behavioral effects of dipropyltryptamine in rats: evidence for 5-HT1A and 5-HT2A agonist activity. https://doi.org/10.1097/fbp.0b013e3281f19ca01
- Gatch MB, & Forster MJ. (2023). The Psychedelic N,N-Dipropyltryptamine Prevents Seizures in a Mouse Model of Fragile X Syndrome via a Mechanism that Appears Independent of Serotonin and Sigma1 Receptors. https://doi.org/10.1021/acsptsci.3c0013712
- Neukamm MA, Vogt S, Graw M, & Peschel O. (2024). A fatal case of aspiration due to consumption of the hallucinogenic tryptamine derivative dipropyltryptamine (DPT). https://doi.org/10.1016/j.jpba.2023.1159591
- Nichols DE. (2016). Psychedelics. https://doi.org/10.1124/pr.115.01147812
- Johnson MW, Griffiths RR, Hendricks PS, & Henningfield JE. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. https://doi.org/10.1016/j.neuropharm.2018.05.0121
- William A. Richards, John C. Rhead, Francesco B. Dileo, Richard Yensen, & Albert A. Kurland. (1977). The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients. https://doi.org/10.1080/02791072.1977.104720201
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/latest/text1
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/latest/details1
- Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances. ejustice.just.fgov.be (n.d.). https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel1
- Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances. ejustice.just.fgov.be (n.d.). https://www.ejustice.just.fgov.be/mopdf/2017/09/26_1.pdf#Page1701
- Bekendtgørelse om euforiserende stoffer. retsinformation.dk (n.d.). https://www.retsinformation.dk/eli/lta/2026/4051
- Bekendtgørelse om euforiserende stoffer. retsinformation.dk (n.d.). https://www.retsinformation.dk/eli/lta/2026/405/pdf1
- Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista (1130/2014). finlex.fi (n.d.). https://www.finlex.fi/fi/laki/ajantasa/2014/201411301
- Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista (1130/2014). finlex.fi (n.d.). https://www.finlex.fi/api/media/statute-consolidated/1074839/media/8500.pdf1
- Anlage NpSG — Indol-3-alkylamine (Neue-psychoaktive-Stoffe-Gesetz Anlage 1). Bundesministerium der Justiz und für Verbraucherschutz / Bundesamt für Justiz (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html12
- Neue-psychoaktive-Stoffe-Gesetz, Anlage 1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
- § 4 NpSG. (2019). https://www.gesetze-im-internet.de/npsg/__4.html12
- Misuse of Drugs Regulations 2017 (S.I. No. 173 of 2017). irishstatutebook.ie (n.d.). https://www.irishstatutebook.ie/eli/2017/si/173/made/en/1
- Misuse of Drugs Regulations 2017 (S.I. No. 173 of 2017). irishstatutebook.ie (n.d.). https://www.irishstatutebook.ie/eli/1977/act/12/section/3/enacted/en/html1
- Ministerial Ordinance designating substances under the Pharmaceuticals and Medical Devices Act. mhlw.go.jp (n.d.). https://www.mhlw.go.jp/bunya/iyakuhin/yakubuturanyou/dl/meisho.pdf1
- Ministerial Ordinance designating substances under the Pharmaceuticals and Medical Devices Act. elaws.e-gov.go.jp (n.d.). https://elaws.e-gov.go.jp/document?lawid=335AC00000001451
- Law on the Entry into Force and Application of the Criminal Law, Annex 2. likumi.lv (n.d.). https://likumi.lv/ta/id/50539-par-kriminallikuma-speka-stasanas-un-piemerosanas-kartibu1
- Law on the Entry into Force and Application of the Criminal Law, Annex 2. likumi.lv (n.d.). https://likumi.lv/ta/id/323173-grozijumi-narkotisko-un-psihotropo-vielu-un-zalu-ka-ari-prekursoru-likumigas-aprites-likuma1
- Law on the Entry into Force and Application of the Criminal Law, Annex 2. likumi.lv (n.d.). https://likumi.lv/ta/id/88966-kriminallikums1
- Misuse of Drugs Act 1975. legislation.govt.nz (n.d.). https://legislation.govt.nz/act/public/1975/0116/latest/DLM436576.html1
- Misuse of Drugs Act 1975. legislation.govt.nz (n.d.). https://legislation.govt.nz/act/public/1975/0116/latest/whole.html1
- Forskrift om narkotika (narkotikaforskriften) (FOR-2013-02-14-199), read with lov om legemidler m.v. (legemiddelloven) § 24. lovdata.no (n.d.). https://lovdata.no/dokument/SF/forskrift/2013-02-14-1991
- Forskrift om narkotika (narkotikaforskriften) (FOR-2013-02-14-199), read with lov om legemidler m.v. (legemiddelloven) § 24. lovdata.no (n.d.). https://lovdata.no/dokument/NL/lov/1992-12-04-1321
- Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2024 poz. 1139). eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2024/1139/text.html1
- Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2024 poz. 1139). eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2021/518/text.html1
- Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych (Dz. U. 2024 poz. 1139). eli.gov.pl (n.d.). https://eli.gov.pl/api/acts/DU/2023/1939/text.html1
- Misuse of Drugs Act 1973. sso.agc.gov.sg (n.d.). https://sso.agc.gov.sg/Act/MDA1973?ProvIds=Sc1-1
- Misuse of Drugs Act 1973. sso.agc.gov.sg (n.d.). https://sso.agc.gov.sg/Act/MDA19731
- Förordning (1992:1554) om kontroll av narkotika. riksdagen.se (n.d.). https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/forordning-19921554-om-kontroll-av-narkotika_sfs-1992-1554/1
- Förordning (1992:1554) om kontroll av narkotika. regeringen.se (n.d.). https://www.regeringen.se/pressmeddelanden/2016/07/flera-nya-amnen-klassas-som-narkotika/1
- 14 nätdroger narkotikaklassas. Drugnews.se (2016-01-21). https://drugnews.se/2016/01/21/14-natdroger-narkotikaklassas/1
- Cabinet of Ministers Resolution No. 770 of 6 May 2000, On Approval of the List of Narcotic Drugs, Psychotropic Substances and Precursors. zakon.rada.gov.ua (n.d.). https://zakon.rada.gov.ua/laws/show/770-2000-%D0%BF?print=11
- Misuse of Drugs Act 1971, Schedule 2. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/21
- Misuse of Drugs Act 1971, Schedule 2, Part I — Class A Drugs. UK Government / legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I1
- Controlled Substances Act; 21 CFR Part 1308. ecfr.gov (n.d.). https://www.ecfr.gov/current/title-21/chapter-II/part-1308/section-1308.111
- Controlled Substances Act; 21 CFR Part 1308. uscode.house.gov (n.d.). https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section813&num=0&edition=prelim1
- Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the DPT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
